People with diabetes who depend on Tandem Mobi insulin pumps to deliver life-sustaining doses around the clock face a direct threat: a software defect can falsely detect a vibration motor failure, shut down insulin delivery, and lock the device entirely. The FDA classified this correction as a Class I recall, its most serious category, on November 5, 2025. The defect is not the first time Tandem Diabetes Care has issued a recall over a fault that renders one of its pumps non-operational. An earlier correction for the t:slim X2 model involved faulty speaker wiring that produced the same outcome: total loss of insulin delivery.
Why a false motor alarm can leave patients without insulin
The Tandem Mobi recall, tracked as event ID 97662, stems from a software design issue that triggers a false vibration motor failure the company labels Malfunction 12. When the error fires, the pump stops delivering insulin and becomes non-operational. For someone whose blood sugar regulation depends on continuous automated dosing, that interruption can rapidly escalate into hyperglycemia or, in severe cases, diabetic ketoacidosis, a potentially fatal condition.
Tandem’s fix is a software update pushed to affected devices running specific firmware versions. But the pattern raises a harder question. The company’s t:slim X2 pump line was subject to a separate Class I recall over faulty speaker wiring designated Malfunction 16, which also stopped insulin delivery and rendered the pump non-operational. Both defects share a common failure path: an alert-related hardware component, whether a vibration motor or a speaker, either malfunctions or is falsely flagged as malfunctioning, and the pump’s software responds by shutting everything down rather than falling back to a safe delivery mode.
That design choice reflects a safety-first philosophy where any doubt about the device’s ability to alert the user leads to a full stop. In theory, that prevents silent failures. In practice, it means a single sensor misread or wiring fault can abruptly cut off therapy for patients who may be asleep, driving, or otherwise unable to respond quickly. The recurring nature of the problem across two distinct Tandem hardware platforms suggests the alert-shutdown logic is deeply embedded in the company’s firmware architecture. Unless Tandem redesigns how its software handles degraded alert hardware, a similar failure mode could surface in future devices built on the same codebase.
FDA recall records and the Tandem correction timeline
The FDA posted the Tandem Mobi correction on its medical device recalls and early alerts page and classified it at the highest severity level. The agency’s recall database entry states plainly that the software design issue causes a false vibration motor failure, that insulin delivery stops, and that the pump becomes non-operational. The correction consists of a software update distributed to users of affected versions.
The t:slim X2 recall followed a parallel track. The FDA identified that action as its most serious type as well. In that case, faulty speaker wiring triggered Malfunction 16, which cut off insulin delivery and terminated communication between the pump and its connected continuous glucose monitor. Both recalls appear on the FDA’s curated index of high-severity medical device actions, underscoring that regulators view any interruption of insulin delivery as an immediate threat to patient safety.
Tandem is not the only insulin pump maker dealing with Class I recalls. According to the FDA, Insulet initiated a removal of certain Omnipod 5 Pods after an early alert issued in March 2026 was formally classified as a Class I recall in April 2026. A separate Omnipod 5 action initiated in May 2026 involved external cannula damage and insulin under-delivery risk. The two Insulet actions differ in their reported failure modes: one FDA database entry describes an internal cannula tear that may lead to cessation of insulin delivery, while a separate entry cites external cannula damage causing insulin to leak around the pod. The conflicting descriptions, one referencing a “removal” and another a “voluntary correction,” reflect the complexity of tracking regulatory actions across FDA databases, but both point to the same core risk: patients not receiving the insulin they need.
Gaps in the Tandem Mobi recall record
Several questions remain open. The FDA’s recall database does not break down how many Tandem Mobi units running the affected software versions are still in active use, nor does it report how many patients actually experienced a pump shutdown versus how many received the update before encountering Malfunction 12. No adverse-event count or injury tally has been publicly released for the Mobi recall. The t:slim X2 correction included some outcome figures in Tandem’s company announcement, but equivalent detail for the Mobi case is absent from the public record.
There is also no published data on how quickly users are completing the software update. For a device that can fail without warning, compliance speed becomes a critical safety variable. If large numbers of patients delay installing the fix, the window of risk remains open even after the recall is technically underway. Without uptake metrics or time-to-update statistics, clinicians cannot easily gauge how many of their patients might still be exposed to abrupt pump shutdowns.
Another gap involves how often Malfunction 12 occurs relative to the total population of pumps in the field. The FDA’s summary describes the defect and its potential consequences but does not quantify the rate at which the false vibration motor failure is triggered. That leaves patients and providers to navigate risk in the abstract. A rare but catastrophic failure may call for one set of responses; a more frequent shutdown pattern could justify more aggressive interventions, such as recommending backup injection plans or temporarily switching devices.
There is also limited visibility into how Tandem tested the updated firmware before release. The recall notice indicates that a software change resolves the issue, but it does not detail whether the company performed stress testing across a range of vibration motor states, battery levels, and environmental conditions. For a safety-critical device, users might reasonably want assurances that the fix not only suppresses false alarms but also preserves the pump’s ability to detect a genuine motor failure and warn the patient in time.
Design lessons and what patients can do now
The repeated appearance of shutdown-inducing alert faults across Tandem products points to a broader design challenge for insulin pumps and other life-sustaining devices. Safety architectures often prioritize avoiding undetected failures, but they must also guard against overreacting to ambiguous signals. A more resilient approach would treat a suspected alert-component problem as a degraded mode rather than an immediate halt to therapy, maintaining basal insulin delivery while escalating warnings through redundant channels such as smartphone apps, wearables, or caregiver notifications.
For patients currently using Tandem Mobi pumps, the first step is to confirm whether their device is running the corrected software. Users should follow Tandem’s instructions for checking firmware versions and installing updates, and they may want to document when the update was applied in case of future questions from clinicians or insurers. People who rely on automated insulin delivery should also have a backup plan-such as rapid-acting insulin pens or syringes-in case the pump becomes non-operational without warning.
Clinicians can play a key role by asking patients about their pump model and software status during routine visits, flagging anyone who may still be on affected versions, and reviewing sick-day and pump-failure protocols. Diabetes educators might incorporate recall awareness into training sessions, emphasizing how to recognize pump alarms, how to transition to manual injections, and when to seek urgent care if high blood sugars do not respond to correction doses.
Regulators, for their part, could help close information gaps by standardizing how recall data are reported. Consistent fields for the number of affected devices, confirmed incidents, injury counts, and update adoption rates would allow patients, providers, and researchers to better understand real-world risk. Clearer terminology around “corrections,” “removals,” and “voluntary” actions would also reduce confusion when multiple database entries describe what appears to be the same underlying problem.
The Tandem Mobi recall underscores how a single line of code tied to an alert component can determine whether a person with diabetes safely receives insulin or abruptly loses access to it. Until device makers redesign their systems to fail in ways that protect therapy first and foremost, every new alert-related defect risks repeating the same pattern: an alarm meant to keep patients safe instead becomes the trigger for the very harm it was supposed to prevent.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
